Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in Children.

ABSTRACT: Infections due to carbapenem-resistant Enterobacteriaceae (CRE) are increasingly prevalent in children and are associated with poor clinical outcomes. Optimal treatment strategies for CRE infections continue to evolve. A lack of pediatric-specific comparative effectiveness data, uncertain pediatric dosing regimens for several agents, and a relative lack of new antibiotics with pediatric indications approved by the US Food and Drug Administration (FDA) collectively present unique challenges for children. In this review, we provide a framework for antibiotic treatment of CRE infections in children, highlighting relevant microbiologic considerations and summarizing available data related to the evaluation of FDA-approved antibiotics (as of September 2019) with CRE activity, including carbapen

SUBMITTER: Chiotos K 

PROVIDER: S-EPMC7047006 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature